One-Year Safety and Efficacy of Tapinarof Cream for the Treatment of Plaque Psoriasis: Results from the PSOARING 3 Trial

•Tapinarof cream 1% once daily was safe, well tolerated, and durably efficacious in patients with mild to severe psoriasis for up to 1 year, with 40.9% complete disease clearance rate, ∼4-month remittive effect, and no tachyphylaxis. •Tapinarof may represent a novel nonsteroidal topical therap y that addresses limitations of current therapies

Source: Journal of the American Academy of Dermatology - June 26, 2022 Category: Dermatology Authors: Bruce Strober, Linda Stein Gold, Robert Bissonnette, April W. Armstrong, Leon Kircik, Stephen K. Tyring, Stephen C. Piscitelli, Philip M. Brown, David S. Rubenstein, Anna M. Tallman, Mark G. Lebwohl Source Type: research